Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tom Gallen

Managing Editor – Europe

Having joined OTC bulletin as a business reporter in 2013, Tom is currently the managing editor and has an intimate knowledge of the global consumer healthcare market, particularly commercial and regulatory issues. He specializes in analyzing the strategies of the world's leading consumer healthcare companies, their business performance, plans and product portfolios.
Set Alert for Articles By Tom Gallen

Latest From Tom Gallen

Croatia's Atlantic Grupa Offloads Food Supplements Unit To PharmaS

PharmaS has struck a deal with Atlantic Grupa which will see it acquire Croatia's leading dietary supplement brand, as well as a product particularly popular with Russian consumers. 
Deals Dietary Supplements

Stada Grows In Russia And CIS With Takeda Deal

Stada will pay $660m for a basket of 20 brands from Takeda to expand its consumer health portfolio in Russia and a number of strategically important CIS markets.

Deals Strategy

Stada Grows In Russia And CIS With Takeda Brands

Stada will pay $660m for a basket of 20 brands from Takeda to expand its consumer health portfolio in Russia and a number of strategically important CIS markets.
Deals Russian Federation

Stada Plots Eastern European Expansion With Walmark Deal

Stada is set to snap up Czech Republic-based Walmark in its second major deal this year as it looks to make good on its promise to rapidly expand its OTC-focused Branded Products business. 
Europe Deals

Zantac Recall And EU Regulatory Issues Hurt Sanofi In Q3

Recalling Zantac in North America over contamination concerns and tightening regulatory requirements in Europe combined to impede growth at Sanofi Consumer Healthcare in Q3. New CEO Paul Hudson says he is still taking time to get to know the business before making any strategic moves.
Sales & Earnings Product Recalls

GSK Plans Further Divestments As Pfizer Brands Drive Up Q3 Sales

GSK is plotting further divestments into next year as it looks to focus its portfolio on key categories and raise funds to cover the costs of integrating Pfizer's Consumer Healthcare business. In the third quarter, GSK's sales advanced double-digits thanks to the inclusion of Pfizer megabrands like Advil and Centrum.
Business Strategies Sales & Earnings
See All
UsernamePublicRestriction

Register